Inhibition of cell death by ribosomal protein L35a

Charles D. Lopez, Gary Martinovsky, Louie Naumovski

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

In order to better understand how tumor cells develop resistance to chemotherapy drugs, we screened a human cDNA expression library in Jurkat cells for cDNA's that conferred resistance to doxorubicin-induced cell death. One of the cDNA's isolated in the screen codes for ribosomal protein L35a, a component of the large subunit of the ribosome. Jurkat cells engineered to overexpress L35a protein were more resistant not only to doxorubicin but also to UV-irradiation, anti-Fas antibody, and serum starvation compared to Jurkat cells expressing endogenous levels of L35a. Jurkat cells overexpressing L35a did not have increased levels of the anti-apoptotic proteins Bcl-2 or Bcl-xL, the drug efflux pump P-glycoprotein, nor altered cellular growth kinetics or total protein synthesis. Our results provide new insight into L35a function and suggest that it may have a role in the cellular response to cytotoxic damage. Since L35a RNA is overexpressed in a significant number of glioblastoma multiforme (GBM) brain tumors, our results may stimulate further investigation into the possible role of L35a in the resistance of GBM to cytotoxic therapy.

Original languageEnglish (US)
Pages (from-to)195-202
Number of pages8
JournalCancer Letters
Volume180
Issue number2
DOIs
StatePublished - Jun 28 2002

Keywords

  • Chemotherapy resistance
  • Glioblastoma multiforme
  • Jurkat
  • L35a
  • Ribosomal protein

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Inhibition of cell death by ribosomal protein L35a'. Together they form a unique fingerprint.

Cite this